IFW



LAHIVE & COCKFIELD LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

Mail Stop Amendment
Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/788,779
For: *A Method for Detecting Disease Associated Mutations*
Inventors: Christine E. Seidman *et al.*
Filed: February 27, 2004
Our Reference No. IGI-111CN2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

11/16/04
Date

Elizabeth A. Hanley, Esq. Registration No. 33,505

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Elizabeth A. Hanley, Esq.
Registration No. 33,505

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Christine E. Seidman *et al.*	Group Art Unit: 1634
Serial No.: 10/788,779	Examiner: Not Yet Assigned
Filed: February 27, 2004	
For: *Method For Detecting Disease Associated Mutations*	
Attorney Docket No.: IGI-111CN2	

Mail Stop Amendment
Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

11/18/04
Date of Signature and of Mail Deposit

By: _____
Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

For the Examiner's convenience in reviewing this continuation application, Applicants submit a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation-in-Part of U.S. Serial No. 08/469,172 , filed June 6, 1995 (Atty. Docket No. IGI-111CN). All references listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the

Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Elizabeth A. Hanley, Esq.
Registration No. 33,505
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 11/16/04

GAD/EAH/MCA/les
Enclosures

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/788,779
Filing Date	February 27, 2004
First Named Inventor	Seidman, Christine E.
Art Unit	1634
Examiner Name	Not Yet Assigned
Attorney Docket Number	IGI-111CN2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	A1	Antonarakis, S.E., "Diagnosis of Genetic Disorders at the DNA Level", *N.E. J. Med.* 320(3):153-163 (1989)	
	A2	Chelly, J. et al., "Transcription of the Systrophin Gene in Human Muscle and Non-Muscle Tissues", *Nature* 333:858-860 (1988)	
	A3	Cotton, R.G., "Detection of Single Base Changes in Nucleic Acids", *Biochem. J.* 263:1-10 (1989)	
	A4	Epstein et al., "Differences in Clinical Expression of Hypertrophic Cardiomyopathy Associated with Two Distinct Mutations in the β-Myosin Heavy Chain Gene", *Clin. Invest.* 86(2):345-352 (1992)	
	A5	Geisterfer-Lowrance et al., "A Molecular Basis for Familial Hypertrophic Cardiomyopathy: A β Cardiac Myosin Heavy Chain Gene Missense Mutation", *Cell* 62:999-1006 (1993)	
	A6	Jarcho, J.A. et al., "Mapping a Gene for Familial Hypertrophic Cardiomyopathy to Chromosome 14q1", *N.E. J. Med.* 321:1372-1378 (1989)	
	A7	Maron et al., "Patterns and Significance of Distribution of Left Ventricular Hypertrophy in Hypertrophic Cardiomyopathy", *Am. J. Cardiol.* 48:418-428 (1981)	
	A8	McKenna et al., "Echocardiographic Measurement of Right Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Relation to Clinical and Prognostic Features", *JACC* 11(2):351-358 (1988)	
	A9	Myers, R. et al., "Detection of Single Base Substitutions by Ribonuclease Cleavage at Mismatches in RNA:DNA Duplexes", *Science* 230:1242-1246 (1985)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/788,779
Filing Date	February 27, 2004
First Named Inventor	Seidman, Christine E.
Art Unit	1634
Examiner Name	Not Yet Assigned
Attorney Docket Number	IGI-111CN2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	B1	Roberts et al., "Direct Diagnosis of Carriers of Duchenne and Becker Muscular Dystrophy by Amplification of Lymphocyte RNA:, *The Lancet* 336:1523-1526 (1990)	
	B2	Rosenzweig, A. et al., "Preclinical Diagnosis of Familial Hypertrophic Cardiomyopathy by Genetic Analysis of Blood Lymphocytes", *N.E. J. Med.* 325:1753-1760 (1991)	
	B3	Sarkar, G. et al., "Access to a Messenger RNA Sequence or Its Protein Product Is Not Limited by Tissue or Species Specificity", *Science* 244:331-334 (1989)	
	B4	Seidman, C. et al., "Mutations in Cardiac Myosin Heavy Chain Genes Cause Familial Hypertrophic Cardiomyopathy", *Mol. Biol. Med.* 8:159-166 (1991)	
	B5	Shapiro, L. et al., "Distribution of Left Ventricular Hypertrophy Cardiomyopathy: A Two Dimensional Echocardiographic Study", *JACC* 2(3):437-444 (1983)	
	B6	Solomon, S.D. et al., "Familial Hypertrophic Cardiomyopathy is a Genetically Heterogeneous Disease", *J. Clinic. Invest.* 86:993-999 (1990)	
	B7	Tanigawa, G. et al., "A Molecular Basis for Familial Hypertrophic Cardiomyopathy: An α/β Cardiac Myosin Heavy Chain Hybrid Gene", *Cell* 62:991-998 (1990)	
	B8	Watkins et al., "Characteristics and Prognosis Implications of Myosin Missense Mutations in Familial Hypertrophic Cardiomyopathy", *N. E. J. Med.* 326:1108-1114 (1992)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	